SUMMARY Organ culture was used to compare gastrin and somatostatin release from cultured antral mucosa obtained from duodenal ulcer and non-ulcer (control) subjects. In response to dibutyryl cyclic AMP (DBCAMP) cultured antral mucosal explants from patients with a history of duodenal ulcer released a greater proportion of antral gastrin into the medium than did antral mucosal explants from non-ulcer subjects. Somatostatin release from antral mucosa from duodenal ulcer patients was substantially less than somatostatin released by antral explants from non-ulcer subjects. In the non-ulcer subjects there was a direct positive correlation between the amounts of antral somatostatin and gastrin released into the culture medium (r=064, <pO.01). In the duodenal ulcer patients, however, there was no correlation between gastrin release and somatostatin release from antral mucosa (r=009; p> 0.2). Results of these studies identify enhanced gastrin release in response to stimulation and decreased release of somatostatin from antral mucosa of duodenal ulcer patients. These alterations in paracrine relationships of antral somatostatin and gastrin in duodenal ulcer subjects may contribute, at least in part, to the pathogenesis of duodenal ulcer disease. The present study was directed to examine and compare potential paracrine relationships between gastrin and somatostatin in antral mucosa of duodenal ulcer and non-ulcer subjects. In vitro organ culture "6-8 of antral mucosa was utilised as an experimental model for the study of similarities and differences between duodenal ulcer and non-ulcer subjects in antral gastrin and somatostatin release during short term culture.
The pathogenesis of duodenal ulcer disease is complex and is believed to involve interactions of multiple factors. -4 In vivo human studies designed to define differences between duodenal ulcer patients and non-ulcer subjects have dealt principally with comparisons of gastric acid secretory rates,5-7 clearance of acid from the stomach8 and duodenum9
and acid mediated feedback inhibition of antral gastrin release. "' Parietal cell function has been examined to determine acid secretory capacity and responsiveness to exogenously administered stimuli" and to endogenously released gastrin. '2 Somatostatin has been shown to possess the capacity to inhibit both gastrin release and gastric acid secretion. Somatostatin is present in large concentrations in antral mucosa in cells intimately proximate to gastrin-containing and -releasing cells and is also released into the circulation. It is as yet uncertain to what extent gastrin release and gastric acid secretion are regulated by local (paracrine) and/or systemic effects of somatostatin.'3 Recent studies have suggested that alterations in local actions (paracrine functions) of somatostatin and gastrin in the antral mucosa may, at least in part, contribute to enhanced gastrin release and increases in gastric acid secretion in duodenal ulcer. '4 15 The present study was directed to examine and compare potential paracrine relationships between gastrin and somatostatin in antral mucosa of duodenal ulcer and non-ulcer subjects. In vitro organ culture "6-8 of antral mucosa was utilised as an experimental model for the study of similarities and differences between duodenal ulcer and non-ulcer subjects in antral gastrin and somatostatin release during short term culture.
Methods

SUBJECTS
The volunteer subjects were nine men with chronic duodenal ulcer disease and nine healthy men without history of peptic ulcer disease. The mean age of the duodenal ulcer subjects was 51 years (range chronic duodenal ulcer disease had the diagnosis established endoscopically during previous evaluation of recurrent symptomatic disease, At the time of study no patient with chronic duodenal ulcer disease had endoscopic evidence of active duodenal or gastric ulcer. None of the study subjects had serious accompanying medical illnesses, previous gastric surgery, or evidence of gastric outlet obstruction. Fasting serum gastrin concentrations were normal (<150 pg/ml) in all ulcer and non-ulcer subjects. All oral medications were discontinued three days before oesophagogastroduodenoscopy.
Complete oesophagogastroduodenoscopy examination was done in all subjects before obtaining antral tissue. Individuals with endoscopic evidence of active duodenal or gastric ulcer, duodenitis or gastritis were excluded from the study. All subjects volunteered for the study and gave written informed consent. The study was (Table 1 ). The mean gastrin content of antral mucosa from duodenal ulcer patients was 22±+0-4 and that for the non-ulcer subjects was 6-7±1-9 ng gastrin/mg explant (p<0-05). Explant gastrin contents, with basal culture medium alone or in the presence of DBCAMP, did not change during the duration of culture (p> 0-1).
Despite variability in antral tissue gastrin contents the per cent of antral gastrin released into the medium under basal (control) culture conditions was similar for both non-ulcer and duodenal ulcer subjects: 6-9±1P0 and 5-8+1-2% total gastrin per hour, respectively (p> 0-1). Dibutryl cyclic AMP (DBCAMP) stimulated gastrin release from antral explants from both duodenal ulcer and non-ulcer subjects ( Table 2 ). The cumulative proportion of gastrin release stimulated by DBCAMP during the six hour culture was substantially greater in the duodenal ulcer patients than control: gastrin release stimulated by DBCAMP from antral mucosa from duodenal ulcer patients was 2-5 times greater than DBCAMP stimulated gastrin release from antral mucosa of non-duodenal ulcer subjects: 16 8±3-3 vs 6-5+1 3% change from basal (p<001), respectively ( Fig. 1) .
ANTRAL SOMATOSTATIN CONTENT
Antral mucosal explants from duodenal ulcer patients contained less somatostatin (129.8±53-4 pg/mg explant) than antral mucosa from the nonulcer subjects (260-5±56-1 pg/mg explant) (p<0.03). subjects. In contrast with these findings, DBCAMP did not affect somatostatin release from antral mucosal explants of any of the nine duodenal ulcer patients.
In the non-ulcer subjects there was a direct (r=0-64) relationship (p<0-01) between the release of antral explant somatostatin and gastrin into the culture medium under basal and stimulated (DBCAMP) conditions (Fig. 3) In the present study, in order to minimise error because of variations in gastrin distribution in the antral mucosa, large numbers of antral mucosal samples (16 to 30 were obtained from each subject and each antral mucosal explant was examined individually. Gastrin release in these studies was expressed as a function of antral gastrin content.
It has been proposed that increased gastrin responsiveness in duodenal ulcer patients may be due, at least in part, to enhanced functional activity of gastrin cells. 31 This study represents the first in vitro comparison of functional cellular responsiveness and potential paracrine interrelationships between antral mucosal gastrin and somatostatin of duodenal ulcer and non-ulcer subjects. Previous studies from our laboratory, using rat antral mucosa in organ culture, demonstrated the capacity of cyclic AMP to stimulate gastrin release and provided evidence in support of a role for endogenous cyclic AMP in stimulating release of antral gastrin.32 In the present study cultured antral mucosal explants from duodenal ulcer subjects were found to release a larger proportion of antral gastrin into the medium in response to DBCAMP stimulation than did antral mucosal explants from non-ulcer subjects. It is not possible to compare directly these in vitro observations to those results of in vivo human investigations. Nonetheless, these studies define demonstrable differences in gastrin cell responsiveness to stimulation in vitro which may reflect fundamental alterations in gastrin cell responsiveness and/or disturbances in antral paracrine influences on gastrin cells of duodenal ulcer patients.
Somatostatin has been proposed as a locally acting paracrine regulator (inhibitor) of antral mucosal gastrin release.3-335 In the present study, somatostatin release from antral mucosa from duodenal ulcer subjects was substantially reduced. Antral mucosa from the duodenal ulcer patients released less than one-third the amount of somatostatin released by antral explants from non-ulcer subjects. In the non-stimulated (basal) state, however, this reduced level of somatostatin release did not affect basal gastrin release from antral mucosa from duodenal ulcer subjects. These findings are contrasted with the significant differences observed in DBCAMP stimulated gastrin release from antral mucosa from duodenal ulcer subjects when compared with control subjects.
These studies support the hypothesis that inhibitory paracrine influences on antral gastrin cells by somatostatin may be disordered in duodenal ulcer, thereby reducing or removing normal somatostatin mediated inhibition of gastrin release. In the nonulcer subjects we found a direct correlation between antral release of somatostatin and gastrin into the culture medium, whereas this correlation was not found with culture of antral mucosa from duodenal ulcer patients (Fig. 3) 
